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Summary
The INK4A locus is often inactivated in human cancer. INK4A encodes for p14ARF and p16INK4A that inhibit growth through
p53 and pRb, respectively. We used RNA interference vectors in transformation assays of human primary cells to analyze
tumor-suppressive functions. We first show that a concerted inactivation of pRb and p53 is required for transformation.
We then demonstrate that loss of p14ARF enhances growth in a p53-dependent manner but has little tumorigenic effect. In
contrast, suppression of p16INK4A expression does not affect cellular proliferation but synergizes with p53 loss to accelerate
growth and cause transformation. Our results delineate the functions of the human INK4A genes in normal and tumorigenic
growth.
Introduction that specifically affect p16INK4A seem to implicate p16INK4A as the
more important tumor suppressor gene product in the human
Most, if not all, human cancers contain genetic alterations in INK4A locus (Ruas and Peters, 1998; Sharpless et al., 2001).
the p53 and the pRb tumor suppressor pathways (Hanahan and However, no experimental data have directly supported this
Weinberg, 2000). In many tumor types, frequent inactivating notion yet.
mutations of the p53 and pRb genes appear, whereas in many With the identification of a set of genetic elements that are
other cancers, these genes are intact and other members of required for the initial neoplastic transformation of human pri-
these pathways are deregulated or inactivated. One such exam- mary cells (Hahn et al., 1999, 2002), it has become possible to
ple is the INK4A locus whose inactivation is seen in a large investigate the individual role of putative tumor suppressors in
proportion of human tumors (recently reviewed in Krug et al., human oncogenesis. By using viral and mutant human genes,
2002). The INK4A locus encodes two growth-inhibitory gene as well as homologous recombination, it became apparent that
products: p16INK4A that activates the tumor-suppressive function the pRb and p53 pathways are involved in this process (Hahn
of pRb by neutralizing cyclinD/cdk4 activity and p14ARF that et al., 1999; Wei et al., 2003). It was previously described (Hahn
counteracts the HDM2-mediated destruction of p53 (Bothner et al., 1999) that transformation of primary human fibroblasts
et al., 2001; Lowe and Sherr, 2003; Pomerantz et al., 1998). is possible by joint expression of the Telomerase reverse tran-
Significantly, in vivo experiments in mouse model systems indi- scriptase subunit (hTERT), oncogenic H-RASV12, and the early
cated that p19ARF, the mouse homolog of p14ARF, plays an impor- region of SV40, which encodes for the viral large and small T
tant protective role in oncogenic transformation and tumori- antigens (LT and st, respectively, Figure 1A). It is likely that the
genicity (Kamijo et al., 1997). In primary mouse embryonic function of LT in these assays is to inactivate pRb and p53
fibroblasts, p19ARF is upregulated in response to oncogenic RAS whereas st supports oncogenic growth by modulating the phos-
expression and is required for the subsequent p53-dependent phatase activity of PP2A (Hahn et al., 2002). Here we used
growth arrest (Kamijo et al., 1997). Also, the expression of this neoplastic transformation model in combination with RNA
p16INK4A is elevated in response to oncogenic stress; however, interference technology to directly assess the individual contri-
this is not essential for the protective response to transformation bution of the human p14ARF and p16INK4A genes to the p53 and
(Serrano et al., 1997). Lastly, nullizigous mice for the p19ARF gene pRb tumor suppressor pathway.
display a large panel of tumors whereas p16INK4A loss causes only
a limited induction of tumors (Krimpenfort et al., 2001; Sharpless Results and Discussion
et al., 2001). Whereas in mice p19ARF seems to be the major
tumor suppressor of the INK4A locus, epidemiological data So far, it has not been clear whether the inactivation of pRb
and p53 by overexpression of LT is the only relevant functionshowing the presence of point mutations and small deletions
S I G N I F I C A N C E
Tumor suppressors are genes found inactivated by mutations or deletions in a subset of human cancers. However, each individual
tumor contains many genetic alterations, complicating the study of the contribution of each variation to tumorigenesis. We studied
the tumor-suppressive functions of the human INK4A locus, which encodes for the p16INK4A and p14ARF genes and is mutated in many
cancers. In mouse model systems, p19ARF plays an important protective role from tumorigenicity whereas p16INK4A loss causes only
a limited induction of tumors. Here we provide evidence that p16INK4A, but not p14ARF, is the major tumor suppressor of the human
INK4A locus.
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Figure 1. Inactivation of p53 and pRb in cellular transformation of primary human fibroblasts
A: Schematic drawing of the transformation protocol of human primary BJ fibroblast using overexpression of hTERT, SV40 Large and small t antigens (LT
and st), and H-RASV12. LT inhibits the Rb and p53 pathways.
B: Stable suppression of pRb and p53 expression in primary human fibroblasts. BJ-ET cells were infected with the indicated retroviral siRNA vectors (pRetroSuper
(pRS)-Hyg) and selected for 10 days with hygromycin. Subsequently, polyclonal pools of cells were infected with a mixture of retroviruses expressing
oncogenic RASV12 and st and selected with blasticidin. The efficiency of st infection was controlled with GFP and was consistently between 50%–60%. After
seven days of selection, cells were harvested and protein expression was analyzed on SDS-PAGE with the indicated antibodies. pRb protein is indicated
by the vertical bar and background staining is indicated by an asterisk.
C: The same cell populations from B were passed through a 3T3 protocol in which at every passage, the relative increase of the cell number was monitored.
D: The same cell population as in B was plated in soft agar to test anchorage-independent growth capability. Visible colonies were counted after three
weeks.
E: Six aliquots of 2  10E6 BJ-ET cells from B were injected into the flanks of three athymic nude mice, and the number of visible tumors was noted after
four weeks.
of LT in the neoplastic transformation model. Therefore, we sient transfection assays in MCF-7 cells, we identified active
siRNA constructs that inhibit p53 and pRb gene expression byinitially examined whether direct inhibition of p53 and pRb ex-
pression is sufficient to replace LT function in transformation more than 90% (Brummelkamp et al., 2002b and Supplemental
Figure S1 at http://www.cancercell.org/cgi/content/full/4/4/of human primary fibroblasts. We used the pSUPER-short in-
terfering (si)RNA expression system to stably suppress the ex- 311/DC1). Then, we retrovirally transduced BJ-primary human
fibroblasts at population doubling (PD) 24 with an amphotropicpression of p53 and pRb (Brummelkamp et al., 2002b). In tran-
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virus encoding for the ecotropic receptor and subsequently siRNA vectors pRS-GFP or pRS-Hyg, and produced viral
stocks. We transduced HeLa/ecotropic-receptor cells with thewith an hTERT-puromycin vector and drug selected to obtain
a polyclonal pool of BJ/ecotropic receptor/TERT cells (BJ-ET). various pRS-Hyg viruses, drug selected for a week, and moni-
tored the expression of p14ARF and p16INK4A with immunoblotThese cells were transduced with siRNA-retroviral vectors
against p53 and pRb, selected for 10 days with hygromycin, analysis. Figure 2B demonstrates the strong and stable inhibi-
tion of p14ARF and p16INK4A genes by the corresponding viralinfected with a mixture of st-GFP and H-RASV12-blasticidin vec-
tors, and drug selected for RASV12 expression to obtain isogenic vectors. Importantly, no crossreactivity was detected despite
the shared exons of these genes, allowing for an independentpolyclonal populations of cells. Immunoblot analysis of cells
directly after the RASV12/st infection demonstrated the powerful investigation of the functions of p16INK4A and p14ARF.
We used the various pRS-GFP knockdown constructs torepression of p53 and pRb expression by the corresponding
siRNA vectors (Figure 1B, lanes 2 and 4). As expected, LT uncover phenotypes of p14ARF and p16INK4A on cellular growth
of primary human cells. We transduced BJ-ET cells with theexpression induced the stabilization of p53 in an inactive form
(lane 5). Importantly, simultaneous suppression of both p53 and respective siRNA vectors and followed the percentage of the
GFP-positive population as a measure for the relative growthpRb was obtained in cells cotransduced with a mixture of siRNA
vectors for these genes (lane 3), indicating that combinatorial advantage or disadvantage that is conferred by the knockdown
compared with the untransduced population that grew underusage of two siRNA vectors is possible in human primary cells.
Next, we tested the tumorigenicity of the different cell popu- identical conditions (Figure 3A). In this assay, we have noticed
that inactivation of either p53 or p14ARF (two different vectors)lations in three types of experiments. First, we examined the
capability of cells to grow in the presence of oncogenic stress granted primary cells a growth advantage compared to control
cells (Figure 3B, left). This effect was highly specific to p53 andinduced by RASV12. Cellular transformation requires the expres-
sion of oncogenic RASV12, but in primary cells, its expression p14ARF as neither the vector-GFP nor many other functional
siRNA constructs displayed such an effect (Figure 3B and dataprovokes a stress response that arrests the cells (Serrano et al.,
1997). As a step toward full transformation, cells must efficiently not shown). As an additional control, we tested the p14ARF-GFP
knockdown construct in MCF-7 cells that lack the p14ARF geneswitch off or escape this stress response. Indeed, BJ-ET cells
with st were growth arrested in response to H-RASV12 expression and found no effect on cellular growth (Figure 3C). We then
examined whether the effect of p14ARF knockdown depends onbut continued to grow when LT was additionally present (Figure
1C). Interestingly, the inhibition of p53, alone or in combination p53 by repeating the experiment in BJ-ET cells that lost p53
function through RNA interference. We found that in the absencewith pRb, was sufficient to overcome the RASV12-induced arrest
to an extent similar as LT. Inhibition of only pRb expression did of p53, loss of p14ARF expression no longer provides a growth
advantage (Figure 3B, middle), indicating that p14ARF limits prolif-not allow any escape from RAS -induced arrest. In a second
experiment, we tested the anchorage-independent growth ca- eration of primary cells in tissue culture conditions in a com-
pletely p53-dependent manner. Equally, the growth-regulatingpability of these cells in a soft agar assay. Only the combined
inhibition of pRb and p53 stimulated colonigenic outgrowth sim- function of p53 was exclusively dependent on p14ARF expres-
sion, as no significant growth advantage was detected in cellsilar to LT (Figure 1D). Single inhibitions of p53 or pRb expression
or excluding RASV12 or st in cells lacking p53 and pRb expression where p53 was inactivated in the background of cells that lost
p14ARF expression (Figure 3B, right). To demonstrate the knock-showed no stimulation of colony outgrowth (Figure 1D). In a
third experiment, we tested the ability of cells to form tumors down of p14ARF in human primary BJ cells, we used a semiquanti-
tative RT-PCR with primers specific for p14ARF, as p14ARF proteinin athymic nude mice. We injected 2 million cells subcutaneously
and monitored tumor growth after 4 weeks. Both the LT overex- in these cells was undetectable by immunoblotting (Figure 3D
and Wei et al., 2001). Stable expression of siRNA against p14ARFpression and the concerted inhibition of pRb and p53 in BJ-ET/
st/RAS allowed for highly efficient tumor formation in mice (Fig- reduced the level of p14ARF mRNA by more than 10-fold (4 PCR
cycles difference), consistent with the results obtained in Helaure 1E). Inactivation of only p53 gave rise to inefficient tumor
growth in some of the mice (2 out of 6), most likely due to cells and comparable to other functional siRNAs, such as p53
(Figure 3D and Brummelkamp et al., 2002b). We used controlincreased genomic instability in the absence of p53 while propa-
gating the cells before the injections. Lastly, mice injected with CDK4 primers to show equal RNA levels in the samples. Similar
to mouse cells, the inactivation of p53 in BJ cells led to stimula-BJ-ET/st/RAS cells, in which only pRb expression was inhibited,
developed no tumors. In conclusion, our results indicate that tion of p14ARF transcription by 5- to 10-fold (Figure 3D and
Eischen et al., 1999). Collectively, these results demonstrate thatloss of p53 is sufficient to overcome RAS-induced oncogenic
stress in primary cells. However, this was not sufficient for full in primary human fibroblasts, the level of endogenous p14ARF
restricts growth in tissue culture conditions in a p53-dependentblown transformation of primary human cells, which also re-
quired the collaborative inhibition of pRb, together with the manner. Second, these results unequivocally demonstrate the
functionality of the p14ARF siRNA constructs in BJ human primaryexpression of hTERT, RASV12, and st.
The INK4A genes (p16 and p14ARF) act upstream of pRb and cells.
In contrast to p14ARF, the inhibition of p16INK4A expressionp53 to inhibit cellular growth (Lowe and Sherr, 2003). To study
their tumor-suppressive role, we have designed siRNA vectors did not alter the growth of primary fibroblasts (Figure 3E, left),
which indicates that the low level of p16INK4A in relatively youngthat specifically suppress the expression of either p16INK4A or
p14ARF by targeting sequences from their unique first exons, as BJ fibroblasts (PD  35) is not yet growth limiting. However,
it is possible that in older BJ cells or in other primary cells,both genes share their exons 2 and 3 (Figure 2A). In transient
transfection assays in HeLa cells, we identified two active con- endogenous p16INK4A is increased to a level that does inhibit
growth. Interestingly, loss of p16INK4A consistently providedstructs against p14ARF and one against p16INK4A (Supplemental
Figure S2 on Cancer Cell website), cloned them into the retroviral growth advantage to cells that already lost p53 function. Further-
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Figure 2. Specific inhibition of expression of p14ARF and p16INK4A
A: Overview of the INK4A locus. The open reading frames of p14ARF (light gray) and p16INK4A (dark gray) are indicated. Dashes above the unique exons
illustrate the position of the siRNA oligos used to target the respective mRNAs.
B: Stable suppression of p16INK4A and p14ARF expression by retroviral transduction. pRS-Hygro retroviruses containing the indicated siRNA constructs were used
to infect HeLa cells. After selection for one week, protein expression was analyzed by immunoblot with the indicated antibodies. Equal loading control is
shown with several background bands (bg).
more, the loss of p53 or p14ARF in cells with reduced p16INK4A either pRb or p16INK4A did not overcome the RAS-induced onco-
genic stress effect.expression also accelerated growth compared to control in-
fected cells (Figure 3E, right). The synergy after loss of p53 or Intriguingly, our results indicate that acute inactivation of
p53 in primary human BJ cells makes them resistant to RAS-p14ARF in a p16INK4A knockdown background was more pro-
nounced than the reciprocal condition because p53 and p14ARF induced oncogenic stress. This result is different from previous
observations indicating that dominant-negative p53 could notknockdown cells had an increased proliferation already. Nota-
bly, loss of p53 or p14ARF did not alter p16INK4A expression levels overcome RAS-induced arrest in IMR90 fibroblasts (Serrano et
al., 1997), that p53/ derivatives of LF1 fibroblasts showed a(Figure 3F), indicating that the acquired growth-limiting effect
of p16INK4A in the p53 knockdown cells is not simply due to an premature senescence phenotype (Wei et al., 2001), and that
BJ fibroblasts expressing an E1A mutant defective in pRb bind-increase in p16INK4A expression after inactivation of p53. There-
fore, inactivation of the p53 pathway leaves p16INK4A as a key ing still arrested in response to RAS (Hahn et al., 2002). Numer-
ous explanations can account for this difference. For instance,inhibitor of cellular proliferation of primary human fibroblasts.
Next, we examined whether p14ARF and p16INK4A function to overexpression of mutant oncogenes, such as E1A or dominant-
negative p53, may by itself upregulate p16INK4A levels, resultingprotect from oncogenic transformation. We introduced onco-
genic RASV12 and st into the various knocked-down BJ-ET cells in the additional requirement of inhibition of the pRb pathway
to allow these cells to grow in the presence of RAS. Furthermore,and drug selected for the infected cells. In response to RASV12
transduction, p16INK4A expression is markedly stimulated (Figure it has been recently suggested that lung fibroblasts such as
IMR-90 or LF1 have higher basal levels of p16INK4A than BJ cells4A, lanes 1 and 2). This stimulation is, to a large extent, counter-
acted by our p16INK4A-siRNA vector (lane 3). Importantly, the (Itahana et al., 2003), perhaps resulting in a different sensitivity
level to the oncogenic stress assault. In another report, it wasintroduction of both p53 and p16INK4A siRNA constructs inhibited
the expression of both genes to an extent comparable to their shown that fibroblasts with biallelic mutation in the p16INK4A gene,
but with apparently normal p14ARF and p53 function, were resis-single knockdowns (lanes 3, 5, and 7). In contrast, p14ARF expres-
sion was undetectable and remained so also after RASV12 ex- tant to RAS-induced premature senescence (Huot et al., 2002).
Here, although p53 function could be induced in these cells bypression (Figure 4B, lanes 3 and 4). As control, we used HeLa
cells to demonstrate both the ability of our antibody to detect UV irradiation, it cannot be excluded that the p53 pathway has
become compromised with regard to oncogenic stress re-p14ARF and the potency of our knockdown construct to negate
p14ARF expression from much higher levels then ever detectable sponse. Therefore, different human cell strains may behave dif-
ferently depending on their initial p16INK4A and p53 activities.in BJ cells, even when transduced with RASV12 (Figure 4B, lanes
1 and 2). Next, we measured the cellular response to oncogenic Loss of the protective response against oncogenic stress
is an essential step toward neoplastic transformation. Our re-RAS stress. As above, control BJ-ET cells activated a protective
growth arrest (Figure 4C). Once more, all conditions containing sults so far support a model in which p53 but not p14ARF is the
main factor in this process. To test this hypothesis further, weloss of p53 continued to grow to various degrees in the presence
of RASV12 while p53-p16INK4A knockdown cells grew significantly analyzed p53 activity by monitoring the level of p21CIP1, a well-
established p53-target gene, in the various knockdown cellsfaster than the rest (Figures 4C and 1C). In contrast, the single
loss of either p14ARF or p16INK4A or combinations of p14ARF with and in the presence or absence of RASV12. Overexpression of
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Figure 3. Growth-inhibiting function of INK4A genes
A: Schematic depiction of the experiment. Cells are transduced with the siRNA-expressing GFP vectors, and the percentage of GFP-positive cells was
determined later by flow cytometry. Increase in the GFP-positive population in time indicates a relative growth advantage whereas decrease indicates
a relative growth disadvantage.
B and E: Primary human BJ-ET cells, that were first transduced with RS-Hyg-53#2, RS-Hyg14#1, RS-Hyg16#4, or control RS-Hyg and selected (BJ53, BJ14, BJ16,
or BJET, respectively), were transduced with the indicated knockdown-GFP vectors and monitored for a period of 10–20 days. In E, right panel, data from
B-left and E-left is copied to allow direct comparison in the same scale.
C: MCF7 cells were infected with the indicated retroviruses and cumulative growth advantage was monitored over 19 days.
D: RNA from BJ-ET cells, stably transduced with the indicated vectors, was collected and subjected to RT-PCR. Relative band intensities of the specific
p14ARF product (marked with an arrow) are indicated by the bar histogram. As control, RT-PCR for CDK4 was performed.
F: p16 expression was analyzed in BJ-cells expressing the indicated knockdown constructs. For comparison with cells with elevated p16 levels, BJET cells
expressing Ras were included (lane 1).
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oncogenic RAS induced p21CIP1 levels (Figure 4D). As expected, in normal culture conditions through p53 but the oncogenic
activation of p53 is p14ARF independent. As the RNAi technologyloss of p53 expression in BJ-ET cells markedly reduced p21CIP1
levels irrespective of RASV12 expression (Figure 4D, lanes 1 and is easily applicable to other fibroblast strains and cell types,
further investigations should reveal the general applicability of3). Intriguingly, and in agreement with our previous results, also
the loss of p14ARF significantly reduced p53 levels and its activity these rules. In addition, it should be possible to use this ap-
(p21CIP1 levels) in BJ cells (lane 2). However, the p14ARF effect proach in the future to define the function of other suspected
was negated by the expression of RASV12 (lanes 2, 4 RAS), tumor suppressors and also to screen for novel genes with
suggesting that in response to oncogenic stress, cells induce tumor-suppressive function using human siRNA-expressing li-
a pathway that activates p53 in a p14ARF-independent manner. braries.
We cannot formally exclude that oncogenic RAS sensitizes cells
Experimental procedureseven to the much reduced levels of p14ARF as found in the
knockdown cells. However, as p14ARF functions to stabilize p53,
Antibodies
the fact that p53 protein levels are not increased by RASV12 Antibodies used in this report were directed against H-Ras (F235), p16
expression argues against this possibility (e.g., Figure 3F, lanes (C-19), p21 (F5), p53 (DO-1), cdk4 (C-22) (Santa Cruz), pRb (IF-8, Signal
1 and 2). Therefore, in our human model system, it is unlikely Transduction Lab.), p14ARF (Ab-1, NeoMarkers), tubulin (YL1/2, ECACC),
SV40 LT, and st (MoAb 419).that p14ARF has an essential protective role against RAS-induced
oncogenic transformation, in contrast to what has been found
Constructsin mice.
pRetroSuper (pRS) was described by Brummelkamp et al. (2002a). pRS-Finally, we asked if the observed synergism between loss
Hygro was generated by replacing the puromycin resistance gene from
of p16INK4A and p53 leads to anchorage-independent growth pRetroSuper by a Hygromycin B resistance gene. pRS-GFP was generated
with st and RASV12. Clearly, the combined loss of p16INK4A and by replacing the puromycin resistance gene by a cDNA encoding enhanced
p53 functions permitted anchorage-independent outgrowth of GFP (Clontech). pMSCV-GFP was generated from pRS-GFP by replacing
the deleted 3LTR sequence with the original 3LTR from pMSCV (Clontech).cells to a similar extent as LT (Figure 4E). All the single knock-
pMSCV-Blast was generated by replacing the puromycin resistance genedowns were completely inactive, most notably, again, the loss
of pMSCV with the Blasticidin resistance gene from pcDNA6 (Invitrogen).of p53 function, which relieved RAS-induced growth arrest. Ad-
pMSCV-GFP-LT and pMSCV-GFP-st were generated by cloning PCR frag-ditionally, all the combinations with p14ARF knockdown showed
ments that encode, respectively, the SV40 large T antigen or the small t
no activity. To further validate transformation, 2 million cells antigen (Srinivasan et al., 1997; Zalvide and DeCaprio, 1995) in pMSCV-
containing the p16/p53 knockdown combination were also in- GFP. Exclusive expression of the respective proteins after infection of BJET
jected into athymic nude mice and found to efficiently give rise cells was verified by Western blotting. pMSCV-Blast Ras was created by
cloning a fragment encoding the V12 mutant of H-Ras in pMSCV-Blast.to subcutaneous tumors (Figure 4F). In addition to the RNAi
pBabepuro-hTERT and LZRS-Neo-ecotropic receptor were described pre-construct directed against exon 1 of p16, we identified a con-
viously (Brummelkamp et al., 2002a; Counter et al., 1998).struct directed against exon 2 of the INK4A locus that inhibits
the expression of both p14ARF and p16INK4A (Supplemental Figure
Identification of siRNA oligos
S3 on Cancer Cell website). As expected, this construct behaved MCF7 or HeLa cells were electroporated as described previously (Agami
similarly to the p16 knockdown construct in a RAS-induced and Bernards, 2000) to more than 95% efficiency with pSuper constructs
growth arrest assay (Figure 4C), in a colony formation assay against the various targets, and 72 hr later, protein expression was analyzed
by SDS-PAGE and Western blotting. The successful 19 nt target sequences(Figure 4E), and in an in vivo tumorigenicity assay (Figure 4F).
used were: RB #2: ATGGAAGATGATCTGGTGA, p14ARF #1: GAACATGGTAs this construct inhibits both p14ARF and p16INK4A expression,
GCGCAGGTTC, p14ARF #2: CATGGTGCGCAGGTTCTTG, p16 #4: GAGGit not only independently verifies the requirement of p16INK4A
AGGTGCGGGCGCTGC, Ex2: GGCAGTAACCATGCCCGCA. The p53 targetdownregulation for tumorigenesis, but also restates the lack of
sequence was described previously (Brummelkamp et al., 2002b).
effect of p14ARF inactivation on this process.
In summary, we describe an approach to directly define Retroviruses
genes, such as p53 and pRb, whose function is to protect Ecotropic retroviruses were generated by transient transfection of the rele-
vant constructs as described (Brummelkamp et al., 2002a) into EcoPack2primary human cells from initiating oncogenic transformation.
(Clontech). Amphotropic retroviruses were generated in Phoenix-AmphoWe used this approach to study the important growth-control-
(Brummelkamp et al., 2002a). Virus containing supernatant was harvestedling functions of the INK4A locus. We find that p16INK4A is the
48–72 hr later and frozen in aliquots.
major tumor suppressor of the human INK4A locus. Namely,
p16INK4A synergizes with p53 to protect primary cells from un- Generation of stable knockdown HeLa cells
restricted growth and from oncogenic transformation. p14ARF, HeLa cells were electroporated with an expression construct expressing
the mouse ecotropic receptor, and two days later, infected with ecotropicon the other hand, regulates growth of primary human cells
Figure 4. p16INK4A and p53 collaborate to protect from oncogenic transformation
A: BJ-ET cells were infected with various knockdown- or LT-expressing viruses and subsequently infected with Ras and st and analyzed as in Figure 1B.
B: BJ-ET cells were transduced with a RASV12 vector (lane 4) or control vector (lane 3) and selected for a week. Cell extracts were analyzed with the
indicated antibodies. For comparison, p14ARF expression was monitored in HeLa cells transduced with control (lane 2) or the p14ARF siRNA vector (lane 1).
C: Growth curves of the indicated knockdown BJ-ET-st-RASV12 cells.
D: Immunoblot analysis of whole-cell lysates from the cells in C before and after RASV12 transduction. Short exposure is indicated by s.e.
E: Soft agar assay with the cells from C.
F: Tumorigenicity in nude mice was assayed as in Figure 1E.
G: A schematic model showing the growth and tumor-suppressive functions of the INK4A genes.
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Referencesretroviruses in the presence of 8 ug/ml polybrene. The cells were selected
with 400 ug/ml Hygromycin B for one week.
Agami, R., and Bernards, R. (2000). Distinct initiation and maintenance mech-
Generation of knockdown BJ-ET cells anisms cooperate to induce G1 cell cycle arrest in response to DNA damage.
BJ primary human skin fibroblasts (ATCC #CRL-2522) were obtained at Cell 102, 55–66.
passage doubling (PD) 22 and maintained by passaging 1:4 when confluent
Bothner, B., Lewis, W.S., DiGiammarino, E.L., Weber, J.D., Bothner, S.J.,in DMEM plus 10% FCS plus antibiotics in 5% CO2 at 37C. The cells were
and Kriwacki, R.W. (2001). Defining the molecular basis of Arf and Hdm2infected at 70% confluency for 16 hr in the presence of 8 ug/ml polybrene
interactions. J. Mol. Biol. 314, 263–277.with an amphotropic retrovirus carrying an expression cassette for the eco-
tropic receptor (Brummelkamp et al., 2002a), followed by infection with an Brummelkamp, T.R., Bernards, R., and Agami, R. (2002a). Stable suppres-
ecotropic retrovirus expressing hTERT (pBabe puro-hTERT) (Counter et al., sion of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2,
1998). The cells (designated BJ-ET) were selected with 1 ug/ml puromycin 243–247.
and frozen down at PD30. BJ-ET cells were then infected with pRS-Hyg
Brummelkamp, T.R., Bernards, R., and Agami, R. (2002b). A system forviruses against the various knockdown constructs. In double infections, the
stable expression of short interfering RNAs in mammalian cells. Scienceviruses were mixed at a ratio of 1:1. Titers were estimated by serial dilutions
296, 550–553.and infection and selection of mouse 3T3 cells in a pilot experiment. BJ-ET
cells expressing SV40LT were generated by double infection with Counter, C.M., Hahn, W.C., Wei, W., Caddle, S.D., Beijersbergen, R.L.,
pMSCVxGFP-LT and pRSHyg. Polyclonal pools were selected for two weeks Lansdorp, P.M., Sedivy, J.M., and Weinberg, R.A. (1998). Dissociation
in 50 ug/ml Hygromycin B (Roche). Subsequently, cells were co-infected among in vitro telomerase activity, telomere maintenance, and cellular im-
with pMSCVblast-RasV12 and pMSCV-GFP-st retroviruses and selected mortalization. Proc. Natl. Acad. Sci. USA 95, 14723–14728.
with 5 ug/ml blasticidin. Small t expression was verified by monitoring %
Eischen, C.M., Weber, J.D., Roussel, M.F., Sherr, C.J., and Cleveland, J.L.GFP-positive cells, which was consistently between 50 and 60%, and by
(1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-immunoblotting.
induced lymphomagenesis. Genes Dev. 13, 2658–2669.For growth curves, cells were split on a 3T3 protocol in medium con-
taining blasticidin, and the relative increase in cell number was calculated. Hahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbergen, R.L., Brooks,
M.W., and Weinberg, R.A. (1999). Creation of human tumour cells with
Soft agar assay defined genetic elements. Nature 400, 464–468.
In DMEM containing 10% serum, 2  104 cells were resuspended in 2 ml
Hahn, W.C., Dessain, S.K., Brooks, M.W., King, J.E., Elenbaas, B., Sabatini,0.4% low melting point agarose (Sigma type VII, catalog no. A-4018) and
D.M., DeCaprio, J.A., and Weinberg, R.A. (2002). Enumeration of the simianseeded, in triplicate, into six-well plates coated with 1% low melting point
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